Pseudomonas aeruginosa Infections in Patients with Severe COVID-19 in Intensive Care Units: A Retrospective Study

Alexandre Baudet,Marie Regad,Sébastien Gibot,Élodie Conrath,Julie Lizon,Béatrice Demoré,Arnaud Florentin

DOI: https://doi.org/10.3390/antibiotics13050390

2024-04-26

Antibiotics

Abstract:Patients hospitalized in ICUs with severe COVID-19 are at risk for developing hospital-acquired infections, especially infections caused by Pseudomonas aeruginosa. We aimed to describe the evolution of P. aeruginosa infections in ICUs at CHRU-Nancy (France) in patients with severe COVID-19 during the three initial waves of COVID-19. The second aims were to analyze P. aeruginosa resistance and to describe the antibiotic treatments. We conducted a retrospective cohort study among adult patients who were hospitalized for acute respiratory distress syndrome due to COVID-19 and who developed a hospital-acquired infection caused by P. aeruginosa during their ICU stay. Among the 51 patients included, most were male (90%) with comorbidities (77%), and the first identification of P. aeruginosa infection occurred after a median ICU stay of 11 days. Several patients acquired infections with MDR (27%) and XDR (8%) P. aeruginosa strains. The agents that strains most commonly exhibited resistance to were penicillin + β-lactamase inhibitors (59%), cephalosporins (42%), monobactams (32%), and carbapenems (27%). Probabilistic antibiotic treatment was prescribed for 49 patients (96%) and was subsequently adapted for 51% of patients after antibiogram and for 33% of patients after noncompliant antibiotic plasma concentration. Hospital-acquired infection is a common and life-threatening complication in critically ill patients. Efforts to minimize the occurrence and improve the treatment of such infections, including infections caused by resistant strains, must be pursued.

pharmacology & pharmacy,infectious diseases

What problem does this paper attempt to address?

The paper primarily explores the situation of Pseudomonas aeruginosa infections and their antibiotic resistance in COVID-19 intensive care unit (ICU) patients. The specific objectives of the study include:

1. **Describing the development of Pseudomonas aeruginosa infections**: Investigating the occurrence of Pseudomonas aeruginosa infections among COVID-19 patients hospitalized for acute respiratory distress syndrome (ARDS) in the ICU of CHRU-Nancy, France, during the first three waves of the COVID-19 pandemic.

2. **Analyzing the resistance of Pseudomonas aeruginosa**: Assessing the resistance of Pseudomonas aeruginosa strains causing infections to different antibiotics.

3. **Describing antibiotic treatment regimens**: Studying the antibiotic treatment regimens received by these patients and exploring whether adjustments were made during the treatment and the reasons for such adjustments.

The study found that among the 51 patients included, the majority were male (90%), and most patients (77%) had at least one comorbidity. The first detection of Pseudomonas aeruginosa infection occurred approximately 11 days after ICU admission. Additionally, some patients were infected with multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Pseudomonas aeruginosa. The most commonly resistant antibiotic categories included β-lactamase inhibitor combinations, cephalosporins, monobactams, and carbapenems. Most patients received empirical antibiotic therapy, which was later adjusted based on the results of susceptibility testing.

In summary, this paper aims to reveal the trends in the evolution, resistance, and antibiotic treatment of Pseudomonas aeruginosa infections in critically ill COVID-19 patients, with the goal of providing guidance to clinicians to improve the treatment outcomes for these patients.